Structure of the CaMKIIδ/Calmodulin Complex Reveals the Molecular Mechanism of CaMKII Kinase Activation

Peter Rellos³, Ashley C. W. Pike³, Frank H. Niesen, Eidarus Salah, Wen Hwa Lee, Frank von Delft, Stefan Knapp*

University of Oxford, Nuffield Department of Clinical Medicine, Structural Genomics Consortium, Oxford, United Kingdom

Abstract

Long-term potentiation (LTP), a long-lasting enhancement in communication between neurons, is considered to be the major cellular mechanism underlying learning and memory. LTP triggers high-frequency calcium pulses that result in the activation of Calcium/Calmodulin (CaM)-dependent kinase II (CaMKII). CaMKII acts as a molecular switch because it remains active for a long time after the return to basal calcium levels, which is a unique property required for CaMKII function. Here we describe the crystal structure of the human CaMKIIδ/CaM complex, structures of all four human CaMKII catalytic domains in their autoinhibited states, as well as structures of human CaMKII oligomerization domains in their tetradecameric and physiological dodecameric states. All four autoinhibited human CaMKIIs were monomeric in the determined crystal structures but associated weakly in solution. In the CaMKIIδ/CaM complex, the inhibitory region adopted an extended conformation and interacted with an adjacent catalytic domain positioning T287 into the active site of the interacting protomer. Comparisons with autoinhibited CaMKII structures showed that binding of calmodulin leads to the rearrangement of residues in the active site to a conformation suitable for ATP binding and to the closure of the binding groove for the autoinhibitory helix by helix αD. The structural data, together with biophysical interaction studies, reveals the mechanism of CaMKII activation by calmodulin and explains many of the unique regulatory properties of these two essential signaling molecules.

Enhanced version: This article can also be viewed as an enhanced version (http://plosbiology.org/enhanced/pbio.1000426/) in which the text of the article is integrated with interactive 3-D representations and animated transitions. Please note that a web plugin is required to access this enhanced functionality. Instructions for the installation and use of the Web plugin are available in Text S1.

Introduction

Calcium/Calmodulin (Ca²⁺/CaM)-dependent serine/threonine kinases (CaMKs) constitute a family of 81 proteins in the human proteome that play a central role in cellular signaling by transmitting Ca²⁺ signals [1]. Kinases in this protein family are activated through binding of Ca²⁺/CaM to regulatory regions that either flank the catalytic domain or are located in regulatory molecules [2]. Four CaMKII isoforms (α, β, γ, and δ), in addition to about 30 splice variants, are expressed in humans. The α and β isoforms are brain specific and together make up approximately 1% of total brain protein in rodents and up to 2% of total protein in their hippocampus [3]. The γ and δ isoforms are expressed in most tissues, but in comparison have much lower expression levels [4,5]. The unique switch-like properties of CaMKII activation and its extremely high abundance in the brain identified CaMKII as a key regulator of cellular memory and learning [6]. CaMKII is essential for the induction of long-term potentiation (LTP), a long-lasting increase in the efficiency of synaptic transmission between neurons that is believed to be a cellular correlate of memory [7,8]. Stimuli that induce LTP lead to autophosphorylation at T286 in CaMKIIα (T287 in the β, γ, and δ isoforms), thereby resulting in sustained CaMKII activation [9]; mice expressing the CaMKIIα T286A mutant were severely impaired in learning [10]. Several CaMKIIδ variants are highly abundant in myocardial tissue [11,12]. Increased CaMKII activity has been observed in patients with structural heart disease and arrhythmias, where prolonged action potential duration leads to sustained hyperactivation of CaMKII and heart failure [11]. CaMKII proteins form large oligomeric structures. The N-terminal kinase domain is tethered via an autoinhibitory helix and a calmodulin binding site to a C-terminal oligomerization domain that
Author Summary

CaMKII enzymes transmit calcium ion (Ca^{2+}) signals released inside the cell by regulating signal transduction pathways through the small regulatory protein CaM; this Ca^{2+}/CaM complex then binds to and activates the kinase, which phosphorylates other proteins in the cell. Since CaMKs remain active long after rapid Ca^{2+} pulses have dropped they function as molecular switches that turn on or off crucial cell functions in response to Ca^{2+} levels. The multifunctional CaMKII forms of this enzyme – of which there are four in human – are important in many processes including signaling in neurons and controlling of the heart rate. They are particularly abundant in the brain where they probably play a role in memory. CaMKII forms an exceptionally large, dodecameric complex. Here, we describe the crystal structure of this complex for each of the four human CaMKII catalytic domains in their autoinhibited states, a complex of CaMKII with Ca^{2+}/CaM, as well as the structure of the oligomerization domain (the part of the protein that mediates complex formation) in its physiological dodecameric state and in a tetradecameric state. Detailed comparison of this large body of structural data together with biophysical studies has allowed us to better understand the structural mechanisms of CaMKII activation by CaM and to explain many of the complex regulatory features of these essential enzymes.

organizes the enzyme into ring-shaped oligomers. Three-dimen-
sional reconstruction of single-particle electron microscopy images revealed dodecameric assemblies for all purified homogeneous full-
length CaMKII isozymes [13,14]. In contrast, tetradecamers were detected in the crystal structures of isolated oligomerization domains. This non-physiological oligomerization state has been attributed to the absence of the kinase domain [15,16].

The cellular regulation of CaMKII activity is the outcome of a complex interplay between protein localization, heterooligomeriza-
tion, local Ca^{2+}/CaM concentrations, CaMKII autophosphoryla-
tion, and dephosphorylation of CaMKII by phosphatases [2,17]. The structure of the isolated Caenorhabditis elegans CaMKII (CeCaMKII) kinase domain in its autoinhibited state provided the first insight into the molecular mechanism of CaMKII regulation [18]. In this structure the inhibitory domain forms a helix that binds tightly to the substrate binding pocket preventing access of substrates. Interestingly, the regulatory domains of two catalytic domains interacted as antiparallel coiled-coils in the CeCaMKII substrate binding pocket, thereby making it available for autophosphorylation by an adjacent kinase molecule. Analysis of this co-crystal structure, structures of all human isozymes in their autoinhibited state, and in-solution association studies showed that binding of Ca^{2+}/CaM triggers large structural changes in the kinase domain as well as in the CaMKII regulatory domain that together lead to allosteric kinase activation. Furthermore, we also describe the structure of an oligomerization domain in its physiological, dodecameric state. Based on the comparison of this large body of structural information and biochemical characterization we propose a model that explains the substrate recognition leading to Ca^{2+} / CaM-dependent allosteric activation of human CaMKIIs.

Results

Structures of Autoinhibited Human CaMKII Isozymes

To date, our understanding of the molecular mechanisms that de
fine the CaMKII autoinhibited state are based on the structural
model of the C. elegans CaMKII orthologue (CeCaMKII). This crystal structure shows an occluded substrate binding site, rearrangements in the ATP binding site that disturb co-factor binding and a remarkable dimeric assembly involving the inhibitory helix and the CaM binding motif (corresponding to residues K293-F313 in CaMKIIγ) [18]. CeCaMKII and human CaMKIIγ share ∼77% sequence identity. We were interested in determining whether regulatory mechanisms suggested based on the crystal structure of CeCaMKII would be conserved in human CaMKII isozymes. To address this, we determined the structures of all human CaMKII isozymes in their autoinhibited state. The structures were refined at resolutions ranging from 2.25 Å (CaMKIIγ) to 2.4 Å (CaMKIIβ). Details of the diffraction data statistics and refinement have been summarized in Table S1. Importantly, whereas the crystallized constructs of the α and β isozymes contained the catalytic domain and the inhibitory region but only a part of the Ca^{2+}/CaM binding motif, the constructs of both CaMKIIγ and CaMKIIδ additionally contained the entire regulatory region as well as a part of the unstructured linker to the association domain. The boundaries used for the crystallized proteins are shown in the boxed sequence inserts in Figure 1A and are indicated in the sequence alignment in Figure S1. As expected, based on the high sequence homology, all structures exhibited a high degree of structural similarity. The activation segments were all well-ordered and helix αC was correctly positioned for catalysis as indicated by formation of the conserved salt bridge between E60 located in αC and lysine K41, which is a hallmark of the active kinase conformation [30] (Figure S2).

Similar to the C. elegans orthologue, the substrate binding site is blocked by the regulatory domain in all human CaMKIIis (Figure 1B). However, dimeric association as in CeCaMKII, i.e., mediated by the
regulatory domain, was not observed for any of the autoinhibited human isozymes. As mentioned above, the C termini of the crystallized isozymes extended well beyond the Ca\(^{2+}\)/CaM binding site (in CaMKII\(d\), including the linker region up to S333). However, the autoinhibitory helices in all isozymes were structured only up to residue 302. Different crystal forms were observed, containing one (CaMKII\(d\)), two (CaMKII\(a\) and CaMKII\(d\)), or four molecules (CaMKII\(b\)) in the asymmetric unit. However, no indication of a conserved dimer interface was evident within the crystals with packing contact regions typically involving small and diverse surface areas. However, evidence that dimerization occurs in solution was found using analytical ultracentrifugation (AUC) sedimentation velocity experiments for all CaMKII catalytic domains (exemplified by CaMKII\(d\) in Figure 1C), thus supporting studies that identified inactive CaMKII as paired (dimers) in cells [19]. The affinities, as estimated from the proportions between the areas of the peaks for monomeric and dimeric species, were weak (\(K_D\) of 200–600 \(\mu\)M), but due to the high effective concentrations of catalytic domains in the context of the holoenzyme, the observed interactions are likely to be biologically relevant (Table S2). Similar association constants were observed for all human CaMKIIs independent of the construct length, suggesting that dimerization is not mediated by the regulatory domain in human CaMKIIs. To test this hypothesis, we repeated the AUC experiments in the presence of an isolated regulatory domain peptide that spans the autoinhibitory region as well as the Ca\(^{2+}\)/CaM binding site (CaMKII\(d\) residues 282–310).

Figure 1. Structural features of CaMKII and dimerization of the kinase domain. A) Domain organization of CaMKII. The catalytic, regulatory and association domains are labelled, and predicted unstructured regions are shown in red. Sites of regulatory phosphorylation and oxidation are indicated. N- and C-terminal boundaries of the crystallized catalytic domain constructs are highlighted by boxed-in residues within the insets. The C-terminal boundary of CaMKII\(\delta\), which is C-terminal to the range depicted (S333) has not been included in the figure. The organization of the autoinhibitory and the Ca\(^{2+}\)/CaM binding domain is shown in the boxed alignment below the cartoon. For comparison, the sequence of the C. elegans (Ce) orthologue has also been included in the alignment. Secondary structural elements observed in the autoinhibited CaMKII\(\delta\), CaMKII\(\delta\)/Ca\(^{2+}\)/CaM, and C. elegans structure are shown above the alignment. The regions encompassing the Ca\(^{2+}\)/CaM binding and autoinhibitory domains are highlighted in blue and green, respectively, and the phosphorylation sites are highlighted in yellow. B) Structural overview of the autoinhibited CaMKII\(d\) kinase domain refined at 2.3 Å resolution. The inhibitor bound at the ATP site is shown in surface representation in light-green, the activation segment is highlighted in magenta and main secondary structural elements are labelled. C) AUC sedimentation velocity experiment showing self-association of CaMKII\(\delta\) in absence (black line) and presence (red line) of a substrate-competitive peptide. The shift in sedimentation coefficient upon peptide binding is indicated by an arrow.

doi:10.1371/journal.pbio.1000426.g001
Interestingly, no change in the proportion between the peaks was observed (red trace in Figure 1C), suggesting that binding of the peptide did not interfere with dimerization in human CaMKIIs. Binding of the peptide led to a significant shift towards smaller sedimentation coefficients, suggesting that interaction with the peptide induces a conformational change that leads to increased friction. Based on these data, it is tempting to speculate that binding of the peptide displaces and subsequently causes unfolding of the inhibitory helix and the Ca\textsuperscript{2+}/CaM binding site, as observed in the structure of the Ca\textsuperscript{2+}/CaM complex.

Structural Reorganization of the Catalytic and Inhibitory Domains Induced by Ca\textsuperscript{2+}/CaM Binding

We were interested in exploring the structural consequences of Ca\textsuperscript{2+}/CaM binding on CaMKII and determined the structure of the CaMKII\textsubscript{8}/Ca\textsuperscript{2+}/CaM complex (Figure 2B). The structure of the complex comprised the catalytic and the regulatory domain of CaMKII (residues 1–333) and full length human calmodulin, and was refined at 1.9 Å resolution to an R/R\textsubscript{free} of 16.1 and 19.9%, respectively (Table S1). In the complex, the regulatory region no longer interacted with its corresponding catalytic domain (Figure 2B). Instead, the conformation of the inhibitory region adopted an extended conformation, in sharp contrast to its helical secondary structure in autoinhibited CaMKII (Figure 2A). The observed extended conformation allowed interaction between the inhibitory region and the substrate binding site of an adjacent catalytic domain. Most notably, T287 was aligned in a position suitable for phosphoryl transfer (Figure 2B). Thus, the structure effectively “captures” CaMKII\textsubscript{8} in the process of transphosphorylation by a neighboring kinase molecule. The Ca\textsuperscript{2+}/CaM binding region exhibits equally significant structural changes compared to the autoinhibited kinase. Although this region displays either an extended or partially disordered conformation in all human autoinhibited CaMKII\textsubscript{s}, it adopts an entirely helical secondary structure in the Ca\textsuperscript{2+}/CaM complex (Figure 2C).

The CaMKII\textsubscript{8}/Ca\textsuperscript{2+}/CaM co-crystal structure revealed that phosphorylation at T287 is not the only mechanism that prevents the regulatory region from rebinding to the lower kinase lobe. In the complex, helix zD blocked the access to the binding site for the inhibitory helix by a significant reorientation of this helix with respect to the autoinhibited kinase; E106 and Y107, for instance, are displaced by more than 10 Å from their position (Cz) in the autoinhibited kinase and block the binding groove for the inhibitory helix (Figure 2D). The movement of zD has another important consequence which results in structural changes within the kinase active site: E97, which is oriented away from the ATP binding site in autoinhibited CaMKII\textsubscript{s}, is positioned in a conformation that allows coordination of the ATP co-factor in the CaMKII\textsubscript{8}/Ca\textsuperscript{2+}/CaM complex. This transition has been previously proposed based on in silico molecular dynamics simulations using the autoinhibited CeCaMKII\textsubscript{2} structure in which the regulatory region was deleted [18]. It is well known that the affinity of CaMKII for ATP is significantly reduced in the absence of Ca\textsuperscript{2+}/CaM [29,31,32–34]. E97 is highly conserved in kinases and plays a major role in recruiting ATP by forming interactions with the sugar moiety [35]. Similar conformations involving altered orientations of E97 that lead to kinase inactivation have been observed in autoinhibited structures of CaMKI [36] and twitchin [37], suggesting that reorientation of zD is a common regulatory mechanism in CaMKs. An animation that illustrates the conformational changes that take place during Ca\textsuperscript{2+}/CaM-dependent CaMKII activation has been embedded in the enhanced version of the manuscript (Datapack S1).

Substrate Recognition of the T287 Phosphorylation Site

Transphosphorylation of T287 (T296 in CaMKII\textsubscript{b}) by a catalytic domain present in the same holoenzyme has been described as the molecular switch that leads to constitutive and Ca\textsuperscript{2+}/CaM-independent CaMKII activity [4,21,22]. The sequence flanking T287 represents a typical CaMK consensus substrate site [38]. The structure of the CaMKII\textsubscript{b}/Ca\textsuperscript{2+}/CaM complex revealed how the regulatory region flanking T287 is recognized as a substrate: The arginine residue in position -3 (R284)—a hallmark of CaMK substrate recognition—exhibits two conformations and forms multiple polar interactions with the zD residues E100 and E97 (Figure 3A). The conformations of residues interacting within the substrate binding site were well defined in the electron density (Figure 3B). The structure of this substrate complex is similar to a CeCaMKII/pentapeptide complex published recently [20].

We used analytical ultracentrifugation (AUC) to determine whether the CaMKII/Ca\textsuperscript{2+}/CaM heterodimer forms in solution and to estimate affinities for the T287-substrate interaction. In agreement with our structural data, sedimentation velocity experiments measured on the CaMKII\textsubscript{b}/Ca\textsuperscript{2+}/CaM complex revealed apparent molecular weights that correspond well to the calculated mass of the complex. The experiments also revealed the presence of oligomers containing two or more copies of the CaMKII/Ca\textsuperscript{2+}/CaM heterodimer (Figure 3C). We estimated dissociation constants (K\textsubscript{D}) of 50 μM and 120 μM, for this self-association for the α and δ isozymes, respectively (Table S2). To further investigate whether the substrate binding pocket was indeed the interacting interface, we performed sedimentation velocity experiments in the presence of a substrate-competitive peptide. When a peptide derived from CaMKII\textsubscript{b} residues 292–310 was included, we observed only free Ca\textsuperscript{2+}/CaM and the CaMKII\textsubscript{b}/Ca\textsuperscript{2+}/CaM heterodimer in solution, but no higher association species. This experiment confirmed that the observed association is mediated by the substrate binding pocket recapitulating what was observed in the crystal structure of this complex.

Recognition of the CaMKII\textsubscript{δ} T307 Autophosphorylation Site

In inactive synapses, slow autophosphorylation at T306 (T307 in CaMKII\textsubscript{b}) accumulates a CaMKII pool of subunits that cannot be activated by Ca\textsuperscript{2+}/CaM and requires phosphatase activity for reactivation [39,40]. The sequence flanking T307 represents a site that is incompatible with CaMKII consensus substrate requirements, raising the question as to how this regulatory phosphorylation site would be recognized as a kinase substrate. In the CaMKII\textsubscript{δ} structure, T307 was bound to the substrate binding site and oriented in an identical fashion to that observed for T287 in the transphosphorylating complex. The T307-containing region adopts an unusual turn conformation not previously seen in kinase substrate complexes. This unusual binding mode was stabilized by hydrophobic interactions of the conserved residues I304 and L305 that bound inside a deep cavity formed by residues located in the P1 loop and in helix 3G (Figure 4A). This hydrophobic anchor allows recognition of this non-consensus substrate site, thus providing insight into how T307 is recognized as a δ-<sub>α</sub>-autophosphorylation site.

Binding of Ca\textsuperscript{2+}/CaM

Ca\textsuperscript{2+}/CaM has the ability to bind to a large number of distinct proteins by adjusting the relative orientation of its EF hands [41–43]. Residues in the interface were well-defined and the recognition motif bound tightly within the central cavity of the Ca\textsuperscript{2+}/CaM structure while no stable contacts were made with the kinase domain. The Ca\textsuperscript{2+}/CaM interaction involved the CaMKII
Figure 2. Structure of the CaMKIIδ/Ca\(^{2+}\)/CaM complex. A) Ribbon diagram of the autoinhibited CaMKIIδ kinase featuring the regulatory domain blocking the substrate binding site. Regulatory phosphorylation sites (T287, T306, T307) are marked by spheres. The region encompassing the autoinhibitory sequence and the Ca\(^{2+}\)/CaM binding domain are colored green and blue respectively throughout. Helices are colored in orange, beta sheets in light blue, and the ATP-competitive inhibitor is shown in stick representation. B) Ribbon diagram of the CaMKIIδ/Ca\(^{2+}\)/CaM structure showing the regulatory region interacting with Ca\(^{2+}\)/CaM (colored in cyan) and a symmetry-related trans-phosphorylating ‘activating’ catalytic domain (colored in gray). The kinase domain is shown in the same orientation as in A. For clarity, the Ca\(^{2+}\)/CaM associated with the trans-phosphorylating kinase has been omitted in the figure. The phosphorylation site T287 is labeled and highlighted with a sphere. C) Structural
residues 296–316. Comparison with the autoinhibited structures of human CaMKII isozymes revealed that a helical secondary structure was induced upon Ca\(^{2+}\)/CaM binding for the region C-terminal to L300. The interactions between CaMKII and Ca\(^{2+}\)/CaM were largely mediated by hydrophobic contacts in the interface of Ca\(^{2+}\)/CaM and the CaMKII binding helix. Phosphorylation of T306 in CaMKII \(\alpha\) (T307 in other CaMKII isoforms), located within the Ca\(^{2+}\)/CaM binding domain, has been shown to inhibit Ca\(^{2+}\)/CaM binding [29,25]. Moreover, Ca\(^{2+}\)/CaM binding to CaMKII with unphosphorylated T306 effectively prevents phosphorylation of this residue [26]. These data are in agreement with our co-crystal structure that showed that both threonine residues (T306/T307) were deeply buried within the Ca\(^{2+}\)/CaM complex (Figure 4B).

We used isothermal titration calorimetry (ITC) to compare the affinities of Ca\(^{2+}\)/CaM to autoinhibited CaMKII catalytic domains with those of the isolated regulatory domain and catalytic domains of CaMKI and CaMKIV: Human CaMKII kinase domains bound Ca\(^{2+}\)/CaM with affinities between 1.6 and 3.4×10\(^{10}\)Mol\(^{-1}\) (KD: 0.6–0.3 μM) (Figure 4C, Table 1). The determined binding affinities were in agreement with affinities determined for the full-length enzyme [53]. Ca\(^{2+}\)/CaM bound to CaMKI and CaMKIV with >20-times higher affinity. Interestingly, these values compared well with the affinity of the isolated Ca\(^{2+}\)/CaM binding domain (CaMKIIb residues 296–315) (97.3×10\(^{6}\)Mol\(^{-1}\); KD: 10.2nM). Comparison with the affinity of the isolated regulatory domains suggests that an energy barrier of ~2.3 kcal/mol is associated with the release of the inhibitory helix and the Ca\(^{2+}\)/CaM trapping mechanism [33]. A unique feature of the CaMKII interaction is the unfavorable (positive) binding enthalpy. The observation that this thermodynamic fingerprint of the binding to Ca\(^{2+}\)/CaM is shared by all human CaMKIIs, but neither by CaMKI nor CaMKIV, underlines the mechanistic differences between these classes of CaMK.

Oligomeric Assembly of CaMKII

Oligomerization into large ring-like structures is a unique feature of CaMKIIIs and the oligomeric state is crucial for rapid autophosphorylation in trans by catalytic domains present in the same oligomer [44]. The discrepancy between the dodecameric (12-mer) structures determined by electron microscopy [13,14] and the tetr decameric (14-mer) assembly revealed by the crystal structure of the isolated oligomerization domain of the \(C.\ elegans\) orthologue [15] prompted us to crystallize the oligomerizaton domains of human CaMKII isozymes. Here we present the oligomerization domains of the human γ and δ isoforms that were refined at 2.7 and 2.8 A\(^\circ\) resolution, respectively. The quality of the final model was substantially improved by averaging the electron density maps using non-crystallographic symmetry. While isolated domains of the δ isozyme were tetr decameric, the CaMKIIγ oligomerization domain crystallized in its dodecameric state, thus providing a model for the oligomerization state observed in full-length CaMKIIIs. The oligomerization domain formed a hex americ structure with a diameter of 120 A and a height of 60 A surrounding a central cavity of only 17 A (Figure 5A). Thus, the main consequence of the insertion of an additional subunit per ring in the tetr decameric assembly is a considerable widening of the central cavity, to about 33 A.

Each oligomerization domain in the ring also contains a deep cavity that has been suggested to represent a peptide binding site, based on structural homology with peptide-binding domains present in nuclear transport factors and scytalone dehydratase [15]. In support of this hypothesis is the fact that a glycine or an acetate molecule, respectively, originating from the crystallization solution were partially occupying this putative binding site in the structures of the CaMKIIγ and CaMKIIδ oligomerization domains.

We used the structures of the dodecameric oligomerization domain, the CaMKIIb/Ca\(^{2+}\)/CaM complex and the structures of the inactive catalytic domains, to construct models for the full-length enzyme (Figure 5B). In our model of the autoinhibited protein, catalytic domains located in both hexameric rings associate. The pairing was chosen arbitrarily whilst based on the orientation of the helices in the dodecameric oligomerization domain. Binding of Ca\(^{2+}\)/CaM triggers unfolding of the inhibitory helix and releases the kinase domain. This structural reorganization allows T287 to bind to an adjacent kinase domain, leading to autophosphorylation and restructuring of the kinase domain to form a conformation with high affinity for ATP due to reorientation of T2D. Once T287 has been phosphorylated, the kinase domain is released fully active and independent of Ca\(^{2+}\)/CaM, and with its substrate binding site accessible.

Discussion

Four regulatory features distinguish the regulation of CaMKII isozymes from other CaMKs. Firstly, CaMKIIIs form large oligomers bringing catalytic domains into close proximity to facilitate rapid autoactivation. Secondly, autophosphorylation of T287 generates Ca\(^{2+}\)/CaM-independent sustained activity. Thirdly, phosphorylation of T287 increases the affinity of CaMKII for Ca\(^{2+}\)/CaM by more than 10,000-fold, an effect known as CaM-trapping [45]. Fourthly, phosphorylation of T306/T307 leads to prevention of CaMKII activation, due to an interference with Ca\(^{2+}\)/CaM binding. Comparison of the active CaMKII with its inactive autoinhibited structures provides a structural model for the unique switch-like mechanism of CaMKII autoactivation, as well as for its inactivation by autophosphorylation of T307. The different molecular mechanisms of CaMKII activation and inactivation are depicted in Figure 6, and we discuss here the structural background of these regulatory events in the light of the determined structures.

Autophosphorylation of T307 and its neighbor T306 prevents binding of Ca\(^{2+}\)/CaM, resulting in inhibitory autophosphorylation [44]. Moreover, knock-in mice expressing mutants of CaMKII\(\alpha\) incapable of phosphorylation of T306 (e.g. T306A, corresponding to T307 in CaMKIIb) identified this residue as an important site regulating synaptic plasticity [46]. However, if T287 is phosphorylated prior to T307, Ca\(^{2+}\)/CaM-independent activity is induced, whereas prior phosphorylation of T307 prevents activation and autophosphorylation of T287. This illustrates that the sequence of autophosphorylation events is a critical component of CaMKII regulation [47]. In agreement with the observation that ATP binding is impaired in autoinhibited CaMKII, we observed only slow autophosphor-
Structural Mechanism of CaMKII Activation

Figure 3. Details of the substrate-peptide interaction. A) Binding of the substrate sequence, including the regulatory site T287 (corresponding to T286 in the α isozyme), within the regulatory domain to the substrate binding pocket of an interacting catalytic domain. Substrate residues (green carbons) are labeled in bold and substrate positions are labeled with small Arabic numbers. The side chain of R284 forms hydrogen bonds with residues located in helix αD (E97/E100). Carbon atoms in catalytic domain residues are shown in light grey and residues are labeled in black. B) Electron density for the substrate peptide region. A region of the sigmaA-weighted electron density (2mFo-DFc) is shown contoured at 1σ superposed onto the final model. C) AUC velocity experiment showing CaMKI/αCaM association in the absence (black line) and presence (red line) of the substrate competitive peptide encompassing the αCaM binding region sequence. The assignment of the peaks to the oligomeric states (orders of association of CaMKI/αCaM heterodimers) are indicated. doi:10.1371/journal.pbio.1000426.g003

ylation activity of CaMKIβ in vitro minimizing premature phosphorylation of T307 (unpublished data). This phosphorylation is stimulated by interaction with CASK [25,26]. Based on our model of inactive CaMKII, it is likely that binding of CASK leads to an allosteric rearrangement similar to the one observed upon release of the inhibitory helix that results in CaMKII activation and autophosphorylation of T306/T307 by the described non-canonical binding mode of the non-consensus substrate site at T307 in inactive CaMKII.

A recent report showed that Angiotensin II-induced oxidation of the methionines M281/M282 leads to sustained activity of CaMKII in the absence of Ca²⁺/αCaM, inducing apoptosis in cardiomyocytes [48]. The structure of inactive CaMKII suggests that oxidation of M282 would lead to steric clashes with the lower lobe, resulting in destabilization of the autoinhibited state and Ca²⁺/αCaM-independent activation. In the CaMKIIβ/Ca²⁺/αCaM complex, M282 binds into a tight hydrophobic pocket in the substrate binding site, suggesting that oxidation of this residue also interferes with substrate binding and autophosphorylation of T287 (see Figure 3A and 4A). Taken together, our structural data suggest that Met oxidation interferes with both the CaMKII inactive state and autophosphorylation of T287, thus supporting a role of M282 oxidation in CaMKII regulation [48]. The key discoveries of this study were conformational changes that take place upon binding of Ca²⁺/αCaM, resulting in activation of the kinase. These structural rearrangements were identified by detailed comparison between the structures of all autoinhibited CaMKII and the CaMKII/Ca²⁺/αCaM co-crystal structure. Interestingly, CaM did not interact with any other region of the catalytic domain of CaMKII outside the helical recognition motif. The absence of a specific docking site for Ca²⁺/αCaM on the catalytic domain proper presumably allows this versatile modulator to interact with a large number of highly diverse proteins by inducing structural rearrangements in its target enzymes. Recently, the structure of a complex of Ca²⁺/αCaM with DAPK1 (Death Associated Protein Kinase 1) revealed multiple interactions of Ca²⁺/αCaM with the upper and lower kinase lobe and binding of Ca²⁺/αCaM in an extended conformation [49]. In addition, the substrate binding site in the DAPK1/Ca²⁺/αCaM complex was occluded by Ca²⁺/αCaM, suggesting that a conformational change would need to take place to fully activate DAPK1. CaMKII is only distantly related to DAPK1, and it seems that the interaction with Ca²⁺/αCaM and the mechanism of activation of these two CaMKs are fundamentally different.

All four CaMK II isozymes were crystallized with ATP-competitive inhibitors that are relatively non-selective. However, their binding modes (see Figure S3) may nonetheless provide valuable chemical starting points for structure-based design of selective and potent inhibitors for the treatment of diseases. CaMKII have been implicated in heart failure [50], arthritis [51], and certain types of cancer [52–54]. The detailed comparison of the large body of structural information presented here provides the first insight into how an intact CaMKII catalytic/regulatory domain interacts with Ca²⁺/αCaM. However, issues such as how catalytic domains pair together or how activation resulting from trans-phosphorylation is propagated in the holoenzyme would be best addressed by structures of full length CaMKII, an effort that is ongoing in our laboratory.

Material and Methods

Protein Expression and Purification

Expression constructs comprised the following residues of human CaMKs: CaMKIα 1–333, CaMKIβ 15–301, CaMKII 11–302 and 358–498, CaMKIβ 334–475, CaMKIIα 5–317 and 387–527, CaMKIV 15–340, and calmodulin 1–152.
were cloned into the T7 expression vector pNLC28-Bsa4 by ligation-independent cloning. Proteins were expressed in Escherichia coli BL21(DE3)R3 as fusions to a Tobacco Etch Virus (TEV)–cleavable N-terminal His6 affinity tag. Cells were re-suspended in lysis buffer (50 mM HEPES pH 7.5 at 25°C, 0.3 M NaCl, 20 mM imidazole) in the presence of a protease inhibitor mix (Complete, EDTA-free Protease Inhibitor Cocktail, Roche Diagnostics Ltd.) and lysed using an EmulsiFlex-C5 high pressure homogenizer (Avestin) or, alternatively, by sonication at 4°C. The lysate was bound to a Ni-NTA column, extensively washed (50 mM HEPES pH 7.5, 300 mM NaCl, 20 mM imidazole) and eluted using the same buffer containing 200 mM imidazole. Proteins were dephosphorylated in vitro with the addition of 50 mM MnCl2 and λ-phosphatase overnight at 4°C. The eluted protein was pooled, concentrated and applied to either a Superdex 75 or 200 16/60 HiLoad gel filtration column equilibrated in 50 mM HEPES, pH 7.5, 300 mM NaCl, 10 mM diithiothreitol (DTT). Additional purification by ion-exchange chromatography (HiTrap Q in 50 mM Tris pH 8.0, using 0.1 to 0.7 M NaCl gradients) was used where purification was insufficient. Purity was monitored by SDS-polyacrylamide gel electrophoresis and final samples were concentrated to 10–15 mg/ml. Dephosphorylation of CaMKIIγ was inefficient, preventing TEV-cleavage due to phosphorylation of the TEV recognition motif. The alpha and gamma isoforms were crystallized in fusion with the His6-TEV tag.

Crystallization and X-Ray Data Collection

Crystals were obtained by the sitting drop vapour diffusion method at 4°C using conditions included in Table S1. Inhibitors used for co-crystallization were added to the protein solutions prior to crystallization at a final concentration of 1 mM. Diffraction data were collected on beam-line X10SA at the Swiss Light Source (SLS, Paul-Scherrer Institute, Villigen, Switzerland) from crystals flash-frozen in liquid nitrogen.

Data Processing, Molecular Replacement and Refinement

Data were indexed and integrated using MOSFLM [55] and were scaled using SCALA [56]. Structures were phased by molecular replacement using Phaser [57] with the coordinates of either the C. elegans model of inactive catalytic domain [18] or the refined CaMKIIγ, respectively, as search models. Refinement was carried out using REFMAC5 [38] employing appropriate geometric and non-crystallographic restraints. The models and structure factors have been deposited with PDB accession codes listed in Table S1.

Analytical Ultracentrifugation

Sedimentation velocity experiments were carried out on an Optima XL-I Analytical Ultracentrifuge (Beckman Instruments, Palo Alto, CA) equipped with a Ti-50 rotor. Protein samples were studied at a various concentrations in 10 mM HEPES pH 7.5, containing 300 mM NaCl, 1 mM CaCl2 and 5 mM DTT at 4°C, employing a rotor speed of 50,000 rpm. Radial absorbance scans were collected in one-minute intervals using a double-sector cell. 300 µl aliquots were loaded into the sample channels of double-channel 12-mm centerpieces and 310 µl of buffer into the reference channels. Data were analyzed using SEDFIT [59,60] to calculate s20, w values, using: $s_{20,w} = \left[\frac{M(1-\tau_{p0})}{N_{A}k_{B}T} \right]^{1/3}$.
where $M$ is the molecular weight, $\rho$ is the partial specific volume, $N_A$ is Avogadro’s number and $s_0^{20,w}$ is the sedimentation coefficient corrected to the standard conditions of density, $\rho_0$, and viscosity, $\eta_0$ of water at 20°C, and extrapolated to infinite dilution. Sedimentation equilibrium experiments were performed at 4°C and at a number of protein concentrations. Dissociation constants, $K_D$, were determined from single- and multi-wavelength experiments. Each data set was determined from a single titration experiment. The error was estimated from a repeated experiment (performed for CaMKI, labeled with $\dagger$) employing re-purified CaMKI and re-purified Ca$^{2+}$/CaM. We found that binding constants had an error of approximately two-fold with, however, similar binding enthalpy and stoichiometry.

**Values represent the concentration of the titrant (Ca$^{2+}$/CaM) and the protein (the kinase domain) in the calorimeter. For the experiment on the isolated regulatory domain (CaMKII d- pep: peptide, ARRLGAILTMLATRNF corresponding to Ca$^{2+}$/CaM binding domain residues 296–315 CaMKII d), the peptide was titrated into a solution containing Ca$^{2+}$/CaM. N: Stoichiometry of the interaction determined in the experiment.

doi:10.1371/journal.pbio.1000426.t001

Table 1. Isothermal titration calorimetry data of the interaction of Ca$^{2+}$/CaM with CaMKs.

| Concentration (mM)** | $K_D \times 10^6$ (M$^{-1}$)* | $\Delta H^{obs}$ (kcal/mol)* | $T\Delta S$ (kcal/mol) | $\Delta G$ (kcal/mol) | N  |
|----------------------|-------------------------------|-----------------------------|----------------------|----------------------|----|
| CaMKII d - Ca$^{2+}$/CaM | 0.266/0.012                   | 3.7±0.3                     | $+5.4\pm0.05$        | 13.8                 | $-8.4$ | 0.933 |
| CaMKII d - pep- Ca$^{2+}$/CaM | 0.532/0.038                 | 97.1±10                     | $+4.4\pm0.03$        | 14.7                 | $-10.3$ | 1.020 |
| CaMKIIs - Ca$^{2+}$/CaM | 0.150/0.015                   | 1.7±0.08                     | $+12.1\pm0.13$       | 20.2                 | $-8.0$ | 0.863 |
| CaMKII d - Ca$^{2+}$/CaM | 0.112/0.010                   | 2.9±0.2                     | $+8.9\pm0.08$        | 17.3                 | $-8.4$ | 0.922 |
| CaMKII c - Ca$^{2+}$/CaM | 0.110/0.010                   | 1.9±0.15                     | $+8.6\pm0.1$         | 16.7                 | $-8.1$ | 0.981 |
| CaMKI d - Ca$^{2+}$/CaM | 0.150/0.015                   | 187.0±84                    | $-5.8\pm0.07$        | 4.9                  | $-10.7$ | 1.030 |
| CaMKI d - pep- Ca$^{2+}$/CaM | 0.248/0.024                 | 78.8±21                     | $-5.1\pm0.04$        | 5.1                  | $-10.2$ | 0.930 |
| CaMKIIV - Ca$^{2+}$/CaM | 0.156/0.088                   | 108.0±19                    | $-10.2\pm0.05$       | 0.14                 | $-10.3$ | 0.830 |

*Deviations from a non-linear least squares fit. Each data set was determined from a single titration experiment. The error was estimated from a repeated experiment (performed for CaMKI, labeled with $\dagger$) employing re-purified CaMKI and re-purified Ca$^{2+}$/CaM. We found that binding constants had an error of approximately two-fold with, however, similar binding enthalpy and stoichiometry.

**Values represent the concentration of the titrant (Ca$^{2+}$/CaM) and the protein (the kinase domain) in the calorimeter. For the experiment on the isolated regulatory domain (CaMKII d- pep: peptide, ARRLGAILTMLATRNF corresponding to Ca$^{2+}$/CaM binding domain residues 296–315 CaMKII d), the peptide was titrated into a solution containing Ca$^{2+}$/CaM. N: Stoichiometry of the interaction determined in the experiment.

doi:10.1371/journal.pbio.1000426.t001

Figure 5. Oligomerization domains of human CaMKII d and CaMKII c. A) Comparison between the structures of the dodecameric (CaMKII d) (upper) and tetradecameric (CaMKII c) (lower) arrangements. The rings are viewed looking face-on (left) and side-on (right) B) Model of the autoactivation of full-length CaMKII. For clarity, only one CaMKII dimer is highlighted (protomers shown in green and red, respectively). The model was constructed by manual docking of the kinase domain and the CaMKII/Ca$^{2+}$/CaM complex to the experimental structure of the dodecameric oligomerization domain.

doi:10.1371/journal.pbio.1000426.g005
dependent activation (to the right) is achieved through structural rearrangement of the inhibitory helix caused by Ca\textsuperscript{2+}.

The substrate binding site (depicted as a green surface), and aligns E97 in the active site for ATP binding. As a consequence, the active state of the kinase is blocked (marked as a red cross) due to pT287 and a structural change in the lower kinase lobe that closes the binding site for the helix, restructures the substrate binding site (depicted as a green surface), and aligns E97 in the active site for ATP binding. As a consequence, the active state of the kinase is long-lasting and signaling pathways that lead to changes in gene transcription are activated.

$$K_d = \frac{1}{K_{a,obs} \cdot \varepsilon_{290} \cdot \frac{d}{2}}$$

where $d$ is the optical pathlength and $\varepsilon_{290}$ the extinction coefficient at 290 nm.

**Isothermal Titrination Calorimetry**

ITC data were measured using a VP-ITC titration microcalorimeter from MicroCal, LLC (Northampton, MA). For all experiments the proteins used were dialyzed against 20 mM HEPES pH 7.5, containing 150 mM NaCl, 5 mM DTT and 1 mM CaCl\textsubscript{2}.

Data were measured at 10°C by titrating Ca\textsuperscript{2+}/CaM into CaMKII catalytic domains or peptides into Ca\textsuperscript{2+}/CaM, respectively. The inhibitory peptide sequence used for titrations was ARRKLGAILTTMLATRNF, corresponding to Ca\textsuperscript{2+}/CaM binding domain residues 296–315 in CaMKII\textalpha. Each experiment consisted of a first injection of 2 μl followed by 29 injections of 10 μl injected during 20 s and a spacing of 280 s between injections. Blank titrations (Ca\textsuperscript{2+}/CaM into buffer) were subtracted from the titration data. Data were normalized and evaluated using ORIGIN with a single binding site model. Thermodynamic parameters were calculated using: $\Delta G = \Delta H - T \Delta S = -RT \ln K_d$, where $\Delta G$, $\Delta H$ and $\Delta S$ are the changes in free energy, enthalpy and entropy of binding, respectively.

**Supporting Information**

**Datapack S1** Standalone iSee datapack - contains the enhanced version of this article for use offline. This file can be opened using free software available for download at http://www.molssoft.com/icm_browser.html.

Found at: doi:10.1371/journal.pbio.1000426.s001 (ICB)
glycine residue (G173). In the absence of phosphorylation the
conformational stability of the activation segment is increased by a
hydrogen bond network formed by the catalytic loop R135, the
backbone oxygen of L160, G173 and P172 as well as with the side
chain oxygen of a highly conserved tyrosine (Y191) located in the
loop linking the activation segment with helix \( \alpha F \). In addition, the
tip of the activation segment is stabilized by a conserved cluster of
hydrophobic residues (F172, I161, V164, A170) conserved in all
CaMKII isozymes and most orthologues.

Found at: doi:10.1371/journal.pbio.1000426.s003 (2.55 MB DOC)

Figure S3 Binding of ATP-competitive inhibitors to the four CaMKII isozymes. The binding mode of each inhibitor is shown in the upper panel and the inhibitor structure in the lower panel.

Found at: doi:10.1371/journal.pbio.1000426.s004 (2.53 MB DOC)

Table S1 Structural refinement and data collection.

Found at: doi:10.1371/journal.pbio.1000426.s005 (0.07 MB DOC)

Table S2 Dissociation constants for the formation of dimers of CaMK isozymes and of “dimers of CaMKII Ca\(^{2+}\)/CaM heterodimers” (CaMKII-CaM\(_{2}\)). Protein association was monitored using analytical ultracentrifugation sedimentation velocity experiments, in 10 mM HEPES buffer containing 300 mM NaCl, 0.5 mM CaCl\(_2\) and 5 mM DTT, at 4°C. Distributions of species were analyzed using SEDFIT and dissociation constants were estimated from the proportions between monomer/dimer and heterodimer/heterotetramer peaks, respectively, using \( K_D = c(m)^2/d \), where \( c \), concentration in molar; \( m \), proportion of monomers; \( d \), proportion of dimers.

Found at: doi:10.1371/journal.pbio.1000426.s006 (0.05 MB DOC)

Text S1 Instructions for installation and use of the required web plugin (to access the online enhanced version of this article).

Found at: doi:10.1371/journal.pbio.1000426.s007 (0.75 MB PDF)

Acknowledgments

We would like to thank the laboratory of Prof. Kevan Shokat (University of California) for providing inhibitors for CaMKII\(\beta\) and \(\delta\), and Prof. Neal Waskam (UTHSC-Houston) and Prof. Andy Hudmon (STARK Neuroscience Research Institute, Indianapolis) for their helpful comments on the manuscript.

Author Contributions

The authors\(\#s\) have made the following declarations about their contributions: Conceived and designed the experiments: PR. ACWP FHN FvD SK. Performed the experiments: PR ACWP FHN ES FvD. Analyzed the data: PR ACWP FHN WHL FvD SK. Wrote the paper: PR ACWP FHN WHL FvD SK.

References

1. Manning G, Whyte DR, Martinez R, Hunter T, Sudarsanam S (2002) The protein kinase complement of the human genome. Science 298: 1912–1934.
2. Solomon MF, Waxham MN (2008) Ca\(^{2+}\)/calmodulin-dependent protein kinases. Cell Mol Life Sci 65: 2637–2657.
3. Erondu NE, Kennedy MB (1985) Regional distribution of type II Ca\(^{2+}\)/calmodulin-dependent protein kinase in rat brain. J Neurosci 5: 3270–3277.
4. Hudson A, Schulman H (2002) Neuronal Ca\(^{2+}\)/calmodulin-dependent protein kinase II: the role of structure and autoregulation in cellular function. Annu Rev Biochem 71: 473–510.
5. Tobinatsu T, Fujisawa H (1989) Tissue-specific expression of four types of rat calmodulin-dependent protein kinase II mRNAs. J Biol Chem 264: 17907–17912.
6. Miller SG, Kennedy MB (1986) Regulation of brain type II Ca\(^{2+}\)/calmodulin-dependent protein kinase by autophosphorylation: a Ca\(^{2+}\)-triggered molecular switch. Cell 44: 681–690.
7. Malecka RC, Kauer JA, Perkel DJ, Maik MD, Kelly PT, et al. (1989) An essential role for postsynaptic calmodulin and protein kinase activity in long-term potentiation. Nature 340: 554–557.
8. Malinow R, Schulman H, Tsien RW (1989) Inhibition of postsynaptic PKC or Ca\(^{2+}\)/calmodulin blocks induction but not expression of LTP. Science 245: 862–866.
9. Malinow R (2003) The long-term potential of LTP. Nat Rev Neurosci 4: 923–926.
10. Elgersma Y, Sweatt JD, Giese KP (2004) Mouse genetic approaches to investigating calcium/calmodulin-dependent protein kinase II function in plasticity and cognition. J Neurosci 24: 8149–8155.
11. Couochannel LF, Anderson ME (2000) The role of calmodulin kinase II in myocardial physiology and disease. Physiology (Bethesda) 15: 131–159.
12. Edman CF, Schulman H (1994) Identification and characterization of delta B-CaMK kinase and delta C-CaM kinase from rat heart, two new multifunctional Ca\(^{2+}\)/calmodulin-dependent protein kinase isoforms. Biochim Biophys Acta 1221: 89–101.
13. Gaertner TR, Kolodziej SJ, Wang D, Kobayashi R, Koomen JM, et al. (2004) Comparative analyses of the three-dimensional structures and enzymatic properties of alpha, beta, gamma and delta isoforms of Ca\(^{2+}\)/calmodulin-dependent protein kinase II. J Biol Chem 279: 12484–12494.
14. Kolodziej SJ, Hudmon A, Waxham MN, Stooft JK (2000) Three-dimensional reconstructions of calcium/calmodulin-dependent (CaM) kinase Helphal and truncated CaM kinase Helphal reveal a unique organization for its structural core and functional domains. J Biol Chem 275: 14354–14359.
15. Hoelz A, Nairn AC, Kuriyan J (2003) Crystal structure of a tetradecameric assembly of the association domain of Ca\(^{2+}\)/calmodulin-dependent kinase II. Mol Cell 11: 1241–1251.
16. Rosenberg OS, Deindl S, Comolli LR, Hoelz A, Downing KH, et al. (2006) Oligomerization states of the association domain and the holoenzyme of Ca\(^{2+}\)/CaM kinase II. J Biol Chem 271: 602–604.
17. Griffith LG (2004) Regulation of calcium/calmodulin-dependent protein kinase II activation by intramolecular and intermolecular interactions. J Neurosci 24: 4894–4898.
18. Rosenberg OS, Deindl S, Sung RJ, Nairn AC, Kuriyan J (2003) Structure of the autoinhibited kinase domain of CaMKII and SANS analysis of the holoenzyme. Cell 123: 849–860.
19. Thaler G, Koehl S, Puhl HL, 3rd, Blank PS, Vogel SS (2009) Structural rearrangement of CaMKIIalpha catalytic domains encodes activation. Proc Natl Acad Sci U S A 106: 6369–6374.
20. Chao LH, Pellicena P, Deindl S, Bartisan LA, Schulman H, et al. (2010) Internucleobase capture of regulatory segments is a component of cooperative CaMKII activation. Nat Struct Mol Biol.
21. Miller SG, Patton BL, Kennedy MB (1988) Sequences of autophosphorylation sites in neuronal type II CaM kinase that control Ca\(^{2+}\)-independent activity. Neuron 1: 593–604.
22. Schwerzer CM, Colbran RJ, Kreifer JR, Soderling TR (1983) Ca\(^{2+}\)/calmodulin-dependent protein kinase II. Identification of a regulatory autophosphorylation site adjacent to the inhibitory and calmodulin-binding domains. J Biol Chem 263: 13486–13490.
23. Colbran RJ, Smith MK, Schwerzer CM, Fong YL, Soderling TR (1989) Regulatory domain of calcium/calmodulin-dependent protein kinase II: Mechanism of inhibition and regulation by phosphorylation. J Biol Chem 264: 4800–4804.
24. Patton BL, Miller SG, Kennedy MB (1990) Activation of type II calcium/calmodulin-dependent protein kinase by Ca\(^{2+}\)/calmodulin is inhibited by autophosphorylation of threonine within the calmodulin-binding domain. J Biol Chem 265: 11204–11212.
25. Lu CS, Hodge JJ, Mehren J, Sun XX, Griffith LG (2003) Regulation of the Ca\(^{2+}\)/CaM-responsive pool of CaMKII by scaffold-dependent autophosphorylation. Neuron 40: 1185–1197.
26. Hodge JJ, Mallasseuil P, Griffith LG (2006) Activity-dependent gating of CaMKII autonomous activity by Drosophila CASK. Neuron 51: 327–337.
27. Giese KP, Fedorov NB, Filipkowski RK, Silva AJ (1998) Autophosphorylation at Thr286 of the alpha calcium-calmodulin kinase II in LTP and learning. Science 275: 870–873.
28. Mayford M, Bach ME, Huang YY, Wang L, Hawkins RD, et al. (1996) Control of memory formation through regulated expression of a CaMKII transgene. Science 274: 1676–1683.
29. Colbran RJ (1993) Inactivation of Ca\(^{2+}\)/calmodulin-dependent protein kinase II by basal autophosphorylation. J Biol Chem 268: 7163–7170.
30. Johnson LN, Noble ME, Owen DJ (1996) Active and inactive protein kinases: structural basis for regulation. Cell 85: 149–158.
31. King MM, Shell DJ, Kwiatkowski AP (1988) Affinity labeling of the ATP-binding site of type II calmodulin-dependent protein kinase by 5′-fluorouracilylbenzoyl adenosine. Arch Biochem Biophys 267: 467–473.
32. Shields SM, Vernon PJ, Kelly PT (1984) Autophosphorylation of calmodulin-kinase II in synaptic junctions modulates endogenous kinase activity. J Neurochem 43: 1599–1609.

33. Forest A, Swulius MT, Tse JK, Bradshaw JM, Gaertner T, et al. (2008) Role of the N- and C-lobes of calmodulin in the activation of Ca2+/calmodulin-dependent protein kinase II. Biochemistry 47: 10597–10599.

34. Gaertner TR, Putkey JA, Waxham MN (2004) RC3/Neurogranin and Ca2+.

35. Shields SM, Vernon PJ, Kelly PT (1984) Autophosphorylation of calmodulin-dependent protein kinase I. Cell 34: 875–887.

36. Goldman J, Naism AC, Kurian J (1996) Structural basis for the autoinhibition of calcium/calmodulin-dependent protein kinase I. Cell 84: 393–407.

37. Hu SH, Parker MW, Le JY, Wilce MC, Benian GM, et al. (1994) Insights into autoregulation from the crystal structure of twitchin kinase. Nature 369: 581–584.

38. Miller ML, Jensen L, Diella F, Jorgensen C, Tinti M, et al. (2008) Linear motif atlas for phosphorylation-dependent signaling. Sci Signal 1: ra2.

39. Blitz J, Conner JH, Brown GP, Wong T, Shenolikar S, et al. (1998) Gating of CaMKII by cAMP-regulated protein phosphatase activity during LTP. Science 280: 1940–1942.

40. Wen Z, Guirland C, Ming GL, Zheng JQ (2004) A CaMKII/calcineurin switch controls the direction of Ca2+-dependent growth cone guidance. Neuron 36: 493–505.

41. Kurokawa H, Osawa M, Kurihara H, Katayama N, Tokumitsu H, et al. (2001) Role for CaMKII inhibitory protein suppresses tumor growth by inducing cell cycle arrest via p27 stabilization. J Biol Chem 276: 25524–25532.

42. Meador WE, George SE, Means AR, Quiocho FA (1995) X-ray analysis reveals structural mechanism of CaMKII activation. Faseb J 11: 331–340.

43. Hanson PJ, Schulman H (1992) Inhibitory autophosphorylation of multifunctional Ca2+/calmodulin-dependent protein kinase analyzed by site-directed mutagenesis. J Biol Chem 267: 17216–17224.

44. Meyer T, Hanson PJ, Stryer L, Schulman H (1992) Calmodulin trapping by calcium-calmodulin-dependent protein kinase. Science 256: 1199–1202.

45. Hanson PI, Schulman H (1992) Inhibitory autophosphorylation of CaMKII controls PSD association, plasticity, and learning. Neuron 36: 493–505.

46. Hashimoto Y, Schwerer CM, Colbran RJ, Soderling TR (1987) Autophosphorylation of Ca2+/calmodulin-dependent protein kinase II. Effects on total and Ca2+-independent activities and kinetic parameters. J Biol Chem 262: 1051–1055.

47. Erickson JR, Joiner ML, Guan X, Kirschke W, Yang J, et al. (2008) A dynamic pathway for calcium-independent activation of CaMKII by methionine oxidation. Cell 133: 462–474.

48. de Diego I, Kaper J, Bakalova N, Kursula P, Wilmanns M (2010) Molecular basis of the death-associated protein kinase/calcium/calmodulin regulator complex. Sci Signal 3: ra6.

49. Wang Y, Tandan S, Cheng J, Yang C, Nguyen L, et al. (2008) Ca2+/calmodulin-dependent protein kinase II-dependent remodeling of Ca2+ current in pressure overload heart failure. J Biol Chem 283: 25524–25532.

50. Westra J, Brouwer E, Bouwman E, Dornbos-van der Meer B, Posthumus MD, et al. (2009) Role for CaMKII inhibition in rheumatoid arthritis: effects on HIF-1-induced VEGF production by rheumatoid synovial fibroblasts. Ann N Y Acad Sci 1173: 706–711.

51. Ma S, Yang Y, Wang C, Hui N, Gu L, et al. (2009) Endogenous human CaMKII inhibitory protein suppresses tumor growth by inducing cell cycle arrest and apoptosis through down-regulation of the phosphatidylinositide 3-kinase/Akt/HDM2 pathway. J Biol Chem 284: 24773–24782.

52. Wang C, Li N, Liu X, Zhong Y, Cao X (2008) A novel endogenous human CaMKII inhibitory protein suppresses tumor growth by inducing cell cycle arrest via p27 stabilization. J Biol Chem 283: 11565–11574.

53. Yuan K, Chung LW, Segal GP, Zayzafoon M (2007) alpha-CaMKII controls the growth of human osteosarcoma by regulating cell cycle progression. Lab Invest 87: 938–950.

54. Leslie AGW, Powell H (2007) MOSFLM. 7.01 ed. Cambridge: MRC Laboratory of Molecular Biology.

55. Evans P (2007) SCALA - scale together multiple observations of reflections. 3.3.0

56. Evans P (2007) SCALA - scale together multiple observations of reflections. 3.3.0 ed. Cambridge: MRC Laboratory of Molecular Biology.

57. Leslie AGW, Powell H (2007) MOSFLM. 7.01 ed. Cambridge: MRC Laboratory of Molecular Biology.

58. Evans P (2007) SCALA - scale together multiple observations of reflections. 3.3.0 ed. Cambridge: MRC Laboratory of Molecular Biology.

59. McCoy AJ, Grosse-Kunstleve RW, Storoni LC, Read RJ (2005) Likelihood-enhanced fast translation functions. Acta Crystallogr D Biol Crystallogr 61: 458–464.

60. Marshudson GN, Vagin AA, Dodson EJ (1993) Refinement of macromolecular structures by the maximum-likelihood method. Acta Crystallogr D Biol Crystallogr 53: 240–255.

61. Schuck P (2004) A model for sedimentation in inhomogeneous media. I. Dynamic density gradients from sedimenting co-solutes. Biophys Chem 108: 187–200.

62. Brown PH, Schuck P (2006) Macromolecular size-and-shape distributions by sedimentation velocity analytical ultracentrifugation. Biophys J 90: 4651–4661.